Smart tool for cholesterol after stroke or mini-stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a smart computer tool that helps doctors manage your cholesterol treatment with Evolocumab (Repatha). If you have had a recent stroke or mini-stroke and are already taking this medicine, the tool may help you reach your LDL (bad cholesterol) goal faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke or a mini-stroke (TIA) in the last 3 months. The cause was not a heart problem or irregular heartbeat.
- Your doctor has already prescribed a cholesterol-lowering medicine called Evolocumab (Repatha).
- You have not had a bleeding stroke, brain tumor, or other serious brain condition.
- You haven't taken Evolocumab or a similar medicine in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing the best target for 'bad' cholesterol (LDL) after a type of stroke caused by a small blocked vessel. You would be in one of two groups to see which LDL level helps prevent another stroke the most.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial tests a new cholesterol-lowering drug (Tafolecimab) in people who recently had a stroke or mini-stroke caused by plaque buildup in the arteries. The goal is to see if aggressive treatment can reduce the risk of another event.
This trial tests whether adding a PCSK9 inhibitor to standard statin therapy can help people with narrowing in brain arteries that hasn't caused symptoms yet. The goal is to see if this combination lowers plaque and prevents future strokes.
This study tests whether combining a digital brain-training program with strong cholesterol-lowering medication can help improve thinking and memory in people with narrowing of arteries inside the brain. The goal is to reduce stroke risk and cognitive decline.
This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.